Predicting Loss of Lung Function in Children With Asthma

October 2nd 2022

A longitudinal study aims to identify which children with asthma are more likely to suffer a loss of lung function.

FDA Updates for the Week of Sept. 26, 2022

October 1st 2022

The FDA has approved several new therapies this week, including Amylyx’s oral treatment for ALS, a fourth Avastin biosimilar, a new glaucoma treatment and another indication for Duxipent. The agency also accepted an NDA for therapy for rare immunodeficiency disease.

Simplifying US Healthcare is Something Jennifer Watts of Children’s Mercy Kansas City Would Like to Change About the Industry

September 30th 2022

Watts, chief emergency management medical officer, director of global health and a pediatric emergency medicine physician at Children’s Mercy Kansas City, is one of 10 winners in this year's Emerging Industry Leaders series.

Pipeline Development Outlook and Future Implications of Unbranded Biologics and Biosimilars

September 30th 2022

With his closing thoughts, Kareem Karara looks to the potential pipeline biologic development of biosimilars and unbranded biologics.

Emerging Industry Leaders: Jennifer Watts of Children’s Mercy Kansas City

September 30th 2022

Jennifer Watts, M.D., M.P.H., chief emergency management medical officer, director of global health and a pediatric emergency medicine physician at Children’s Mercy Kansas City, a children’s hospital in Kansas City, Missouri is one of the 10 up-and-coming healthcare leaders featured in the annual Managed Healthcare Executive feature.